

Please join us and your colleagues  
for an engaging discussion

**HEPLISAV-B**<sup>®</sup>  
Hepatitis B Vaccine (Recombinant), Adjuvanted

# Hepatitis B Overview and Innovations in Immunization

**Time:**

**Venue:**

**Address:**

**Name:**

**Phone Number:**

**Email:**

**Please RSVP to your Dynavax Technologies Corporation Representative by**

## **INDICATION**

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

## **IMPORTANT SAFETY INFORMATION**

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).